Floatz logo

Batiraxcept

Clear Cell Renal Cell Carcinoma

Aravive, Inc.protein_peptidePhase 1/2Dormant
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
73/ 100

Competitive context

116 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Girentuximab
Massachusetts General Hospital
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB

View all 50 →

Same molecule, other indications

Batiraxcept is also rated in:

ovarian cancerDormant
C
Indicative ·
39 / 100
View asset →
primary peritoneal carcinomaDormant
C
Indicative ·
37 / 100
View asset →
ovarian carcinomaDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →